Comment on: “Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors”

Cuicui Li; Xiaoyuan Chen; Jingjing Zhang

doi:10.1016/j.jpha.2023.07.010

Volume 13 Issue 9

Sep. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Analysis > 2023 > 13(9): 958-959

Cuicui Li, Xiaoyuan Chen, Jingjing Zhang. Comment on: “Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors”[J]. Journal of Pharmaceutical Analysis, 2023, 13(9): 958-959. doi: 10.1016/j.jpha.2023.07.010

Citation:

Cuicui Li, Xiaoyuan Chen, Jingjing Zhang. Comment on: “Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors”[J]. Journal of Pharmaceutical Analysis, 2023, 13(9): 958-959. doi: 10.1016/j.jpha.2023.07.010

Citation:

PDF( 215 KB)

Comment on: “Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors”

doi: 10.1016/j.jpha.2023.07.010

Cuicui Li^a,b,c,
Xiaoyuan Chen^{a,b,d,e,f
,
,},
Jingjing Zhang^{a,b,d
,
,}

a. Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119074, Singapore;
b. Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117599, Singapore;
c. Department of Nuclear Medicine, Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing, 100050, China;
d. Nanomedicine Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117597, Singapore;
e. Departments of Surgery, Chemical and Biomolecular Engineering, and Biomedical Engineering, Yong Loo Lin School of Medicine and College of Design and Engineering, National University of Singapore, Singapore, 119074, Singapore;
f. Institute of Molecular and Cell Biology, Agency for Science, Technology, and Research (A∗STAR), 61 Biopolis Drive, Proteos, Singapore, 138673, Singapore

Funds:

This work was supported by the National University of Singapore (Grant Nos.: NUHSRO/2021/097/Startup/13, NUHSRO/2020/133/Startup/08, NUHSRO/2023/008/NUSMed/TCE/LOA, NUHSRO/2021/034/TRP/09/Nanomedicine, and NUHSRO/2021/044/Kickstart/09/LOA), National Medical Research Council (Grant Nos.: OFYIRG23jan-0025, OFYIRG23jan-0017, MOH-001254-01, and CG21APR1005), Singapore Ministry of Education Academic Research Fund (Grant Nos.: NUHSRO/2022/093/T1/Seed-Sep/06 and MOE-000387-01), National Research Foundation (Grant No.: CRP28-2022RS-0001), National Natural Science Foundation of China (Grant No.: 82202206), and Beijing Natural Science Foundation (Grant No.: 7224365).

Received Date: Jul. 03, 2023
Accepted Date: Jul. 13, 2023
Publish Date: Jul. 20, 2023

Abstract

FullText(HTML)

References(10)

References

Y. Chen, X. Hou, D. Li, et al., Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors, J. Pharm. Anal. 13 (2023) 367-375.

Y. Kubota, A. Kawazoe, S. Mishima, et al., Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer, ESMO Open 8 (2023), 100762.

K. Shitara, F. Lordick, Y.J. Bang, et al., Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): A multicentre, randomised, double-blind, phase 3 trial, Lancet 401 (2023) 1655-1668.

W. Cao, H. Xing, Y. Li, et al., Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy, Biomark. Res. 10 (2022), 38.

S. Wang, C. Qi, J. Ding, et al., First-in-human CLDN18.2 functional diagnostic pet imaging of digestive system neoplasms enables whole-body target mapping and lesion detection, Eur. J. Nucl. Med. Mol. Imag. 50 (2023) 2802-2817.

C. Zhao, Z. Rong, J. Ding, et al., Targeting claudin 18.2 using a highly specific antibody enables cancer diagnosis and guided surgery, Mol. Pharmaceutics 19 (2022) 3530-3541.

W. Wei, D. Zhang, Y. Zhang, et al., Development and comparison of ⁶⁸Ga/¹⁸F/⁶⁴Cu-labeled nanobody tracers probing Claudin18.2, Mol. Ther. Oncolytics 27 (2022) 305-314.

G. Hu, W. Zhu, Y. Liu, et al., Development and comparison of three ⁸⁹Zr-labeled anti-CLDN18.2 antibodies to noninvasively evaluate CLDN18.2 expression in gastric cancer: A preclinical study, Eur. J. Nucl. Med. Mol. Imag. 49 (2022) 2634-2644.

W. Zhong, Y. Lu, Z. Ma, et al., Development of a humanized VHH based recombinant antibody targeting claudin 18.2 positive cancers, Front. Immunol. 13 (2022), 885424.

L. Kang, C. Li, Z.T. Rosenkrans, et al., Noninvasive evaluation of CD20 expression using ⁶⁴Cu-labeled F(ab')2 fragments of obinutuzumab in lymphoma, J. Nucl. Med. 62 (2021) 372-378.

Relative Articles

Supplements(0)

Cited By

Proportional views